Management Team

Dominique Kleyn, Chief Executive Officer

Dominique joined London Genetics from Imperial College London, one of London Genetics' founding institutions. At Imperial College she was involved in new venture development and management, technology transfer, fund raising and collaborations. The latter include research arrangements with companies such as GlaxoSmithKline, Merck & Co, Johnson & Johnson and Syngenta. In addition, she was a non-executive founder director of Acrobot, Equinox Pharma, GMEC, London Genetics, MicroTestMatrices, Nova Thera (acquired by Medcell) and Protexeon (acquired by Air Products). Dominique has worked on device and diagnostic development at companies such as Unilever, in business development at the Wellcome Foundation, and in consulting at PricewaterhouseCoopers. She has a BSc in Microbiology, an MBA (2006) from Imperial College London and is a Chartered Licensing Professional.

Dr Mark Caulfield, Clinical Director

Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew's Hospital where he developed a research programme in molecular genetics of hypertension. From 1996 he has been National Co-ordinator of the MRC British Genetics of Hypertension (BRIGHT) Study on behalf of five UK universities. In 2000 he successfully bid for £3.1m to create the Barts and The London Genome Centre which now underpins over 40 programmes of research. He was appointed Director of the William Harvey Research Institute in 2002. Dr Caulfield is also Deputy Chair of the London Biobank Regional Collaborating Centre.

Dr Elizabeth Foot, Chief Scientific Officer

Elizabeth Foot graduated in Biochemistry from Bristol University followed by an MSc in Clinical Biochemistry from Surrey University, being based at St Peter’s Hospital, Chertsey, Surrey. After completion, she worked within the specialised NHS clinical biochemistry laboratory at West Park Hospital, Epsom, Surrey investigating female infertility, detection of drugs of abuse and therapeutic drug monitoring. Elizabeth subsequently gained her DPhil working on the role of amylin and CGRP-1 on insulin resistance in skeletal muscle from Oxford University with Dr Brendan Leighton. She continued working on amylin, moving to Clinical Pharmacology group, GlaxoSmithKline to work on their amylin antagonist and diabetes projects. During her subsequent 16 years at GSK, Elizabeth lead numerous early clinical development projects across a broad range of therapy areas, including diabetes, obesity, cardiovascular, critical care and inflammation, as well as leading clinical pharmacology plans for projects through to market and launch. Elizabeth then moved to the Genetics Research group, GSK where she was part of the core project team that developed the business strategy for pharmacogenetics and drove its implementation worldwide throughout the organisation. Within the Genetics group she led multidisciplinary, international teams to provide strategic direction for Neuroscience senior management and clinical project teams on the application and implementation of stratified medicine approaches into clinical development, commercialisation plans and risk management strategies. In April 2009 Elizabeth joined London Genetics Limited as Chief Scientific Officer to guide their scientific strategy for the integration of genetic data and stratified medicine approaches to add value to drug discovery, clinical development and health care delivery.